Pritelivir is under clinical development by AiCuris Anti-infective Cures and currently in Phase III for Simplexvirus (HSV) Infections. According to GlobalData, Phase III drugs for Simplexvirus (HSV) Infections have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pritelivir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pritelivir (AIC-316, BAY-571293) is under development for the treatment of genital herpes type 2 infection (HSV-2) and herpes labialis. The therapeutic candidate is administered orally, topically and through vaginal routes. It is a compound derived from a chemical class of thiazolylamides which acts by targeting helicase-primase.
AiCuris Anti-infective Cures overview
AiCuris Anti-infective Cures (AiCuris) is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. It offers drugs for the treatment of human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company works in partnership with other drug development companies for the development of medicines targeting human cytomegalovirus. It operates research facility in Wuppertal. AiCuris is headquartered in Wuppertal, Germany.
For a complete picture of Pritelivir’s drug-specific PTSR and LoA scores, buy the report here.